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“At a Glance Commentary” 
 
Scientific Knowledge on the Subject: 
 
In 2016, the Sepsis-3 Task Force updated the clinical criteria for sepsis, excluding the need 
for SIRS and introducing a flowchart that comprises the qSOFA and SOFA scores. However, 
the clinical decision-making process cannot rely on risk stratification scores, because a 
decision-aid tool must account for the benefits and harms of clinicians incorporating that tool 
into clinical practice. A clinical decision-making analysis of Sepsis-3 is not yet available. 
 
 
 
 
 
What This Study Adds to the Field: 
 
We demonstrated that qSOFA outperformed SIRS and presented better clinical usefulness in 
patients with community-acquired pneumonia. Among the tools for initial assessment, SIRS 
presented the worst net benefit versus qSOFA and CRB, significantly increasing the risk of 
over-treatment and  being comparable  to  the “treat-all”  strategy.  Among the  tools  for a 
comprehensive assessment, PSI had better predictive performance and net benefit for 
mortality than mSOFA and CURB-65; while mSOFA was more useful when considering 
mortality/ICU admission. Finally, following the Sepsis-3 flowchart resulted in better 
identification of patients at high risk of worse outcomes. 
 
 
 
 
Word count: 3,523 
 
 
"This article has an online data supplement, which is accessible from this issue's table of 
content online at www.atsjournals.org” 
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ABSTRACT 
 
 
 
Rationale: Sepsis-3 Task Force updated the clinical criteria for sepsis, excluding the need for 
systemic inflammatory response syndrome (SIRS) criteria. The clinical implications of the 
proposed flowchart including the quick Sequential (Sepsis-related) Organ Failure Assessment 
(qSOFA) and SOFA scores are unknown. 
 
Objective: To perform a clinical decision-making analysis of Sepsis-3 in patients with 
community-acquired pneumonia (CAP). 
 
Methods: Cohort study including adult patients with CAP from two Spanish university- 
hospitals. SIRS, qSOFA, CRB (Confusion, Respiratory rate and Blood pressure), mSOFA, 
CURB-65 and Pneumonia Severity Index (PSI) were calculated with data from the 
emergency department. We used decision-curve analysis to evaluate the clinical usefulness of 
each score and the primary outcome was in-hospital mortality. 
 
Measurements and Main Results: Of 6,874 patients, 442 (6.4%) died in hospital. SIRS 
presented the worst discrimination, followed by qSOFA, CRB, mSOFA, CURB-65 and PSI. 
Overall, overestimation of in-hospital mortality and mis-calibration was more evident for 
qSOFA and mSOFA. SIRS had lower net benefit than qSOFA and CRB, significantly 
increasing the risk of over-treatment and being comparable to the “treat-all” strategy. PSI had 
higher net benefit than mSOFA and CURB-65 for mortality; while mSOFA seemed more 
applicable when considering mortality/ICU admission. Sepsis-3 flowchart resulted in better 
identification of patients at high risk of mortality. 
 
Conclusions: qSOFA and CRB outperformed SIRS and presented better clinical usefulness 
as prompt tools for CAP patients in the emergency department. Among the tools for a 
comprehensive patient assessment, PSI had the best decision-aid tool profile. 
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INTRODUCTION 
 
Community-acquired pneumonia (CAP) represents a significant infection burden worldwide, 
and it is often complicated by sepsis (1-4). Early recognition of sepsis is fundamental to guide 
treatment, improve outcomes and decrease costs (5-7). In contrast, in patients with 
uncomplicated infection, over-treatment should be avoided to prevent unnecessary harm. 
Sepsis is a syndrome characterized by a dysregulated host response to infection 
leading to life-threatening organ dysfunction (5). In 2016, the Sepsis-3 Task Force updated 
previous recommendations primarily aiming to accurately differentiate between sepsis and 
uncomplicated infection (5). By applying a data-driven approach to identify patients at risk of 
worse outcomes, the Task Force proposed a new clinical definition, removing the need for 
systemic inflammatory response syndrome (SIRS) criteria. Thus, in infected patients, sepsis 
was clinically defined by an increase in Sequential (Sepsis-related) Organ Failure Assessment 
(SOFA) score of 2 points or more. Additionally, a bedside score for risk stratification, namely 
the quick SOFA (qSOFA), has been proposed, which incorporates hypotension, altered 
mental status and tachypnea (5, 8). 
In patients with CAP, several scores have been developed to identify high-risk 
patients and support therapeutic decisions (4, 9). Two of these scores, CURB-65 (Confusion, 
Urea, Respiratory rate, Blood pressure and Age) and PSI (Pneumonia Severity Index) are 
well-validated scores to support CAP management and prognosis (9, 10). Simplifications of 
CURB-65 (i.e., CRB-65 and CRB) (11) have been developed and validated to facilitate the 
risk stratification process; these simplified scores do not require blood tests (12), as in the 
qSOFA. Yet the definitions for hypotension and tachypnea parameters on the CRB tool differ 
from those of the qSOFA. 
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Sepsis-3 will change clinical practice and influence medical decisions. However, 
clinical decision-making cannot rely only on predictive performance measures, such as 
discrimination and calibration (13, 14). Indeed, decision-aid tools must also account for the 
benefits and harms resulting from clinicians’ choice (13, 14). To date, no clinical decision- 
making analysis of Sepsis-3 is available, including the proposed bedside tool (qSOFA) and 
the Sepsis-3 Flowchart, which includes qSOFA and SOFA scores. Therefore, the aim of our 
study was to evaluate three tools for initial assessment (SIRS, qSOFA and CRB) and three 
tools for a comprehensive assessment (SOFA, CURB-65 and PSI) as decision-aid prognostic 
tools in CAP using decision-curves methodology. Additionally, the Sepsis-3 flowchart was 
also applied in this population. 
 
Some of the results of this study have been previously reported in the form of an 
abstract (15). 
 
 
METHODS 
Study design and patients 
 
 
We retrospectively analyzed patients from two cohorts, which prospectively included 
patients aged ≥16 years with a clinical diagnosis of CAP from two Spanish University- 
Hospitals (Hospital Clinic, Barcelona from 1996 to 2015; Hospital Universitario y  
Politecnico La Fe, Valencia from 2012 to 2015). These cohorts had comparable inclusion and 
exclusion criteria and definitions of the variables. Local Research Ethics Committees 
approved both cohorts (Barcelona, Spain – Register: 2009/5451; Valencia, Spain – Register: 
2011/0219). 
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CAP was defined as a new pulmonary infiltrate on chest radiograph upon hospital 
admission and acute symptoms of lower respiratory tract infection (e.g., fever, cough, sputum 
production, pleuritic chest pain). Immunosuppression (i.e., patients taking more than 10 mg  
of prednisone-equivalent per day for at least 2 weeks, on cytotoxic therapy or with acquired 
immunodeficiency syndrome) and active tuberculosis were exclusion criteria. We included 
patients from nursing home. Demographic variables, comorbidities, and physiologic 
parameters were collected in the emergency department (ED). All patients had a complete 
microbiologic evaluation and microbiologic confirmation of CAP was defined according to 
current guidelines (16, 17). In each institution, a dedicated clinical researcher prospectively 
included patients, under the supervision of an experienced pulmonary physician. Patients  
were followed up until hospital discharge, and all survivors were re-examined or contacted by 
phone 30 days after hospital discharge. Further details are reported in previous publications 
(16, 17). 
 
 
Outcomes 
 
Our primary outcome was all-cause in-hospital mortality (5, 8). We also explored two 
secondary outcomes: 1) in-hospital mortality and/or need for critical care support ≥3 days 
(“composite outcome”) (5, 8); 2) 30-day mortality. We defined need for critical care support 
as admission to an intensive care unit (ICU) or high-dependency unit (HDU). 
 
Scores definition 
 
We clustered the six scores in those that might facilitate: a) the clinician’s initial 
decision (SIRS, qSOFA and CRB); and b) clinician’s decision after initial management and 
additional exams (SOFA, CURB-65 and PSI). We adapted the Sepsis-3 flowchart illustrating 
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this approach and the timeline of the clinical decision-making processes involved in the ED 
(Figure 1). 
 
We defined SIRS, qSOFA, CRB, CURB-65 and PSI as originally described (Table 
E1) (5, 8, 9, 12). For SOFA score, we calculated the respiratory, hematological, hepatic, and 
renal systems as originally described. However, we adapted the SOFA calculation for 
neurologic and cardiovascular parameters, using a conservative approach similar to Sepsis-3 
(modified SOFA–mSOFA, Table E1). We used the first clinical signs/symptoms  
documented in the ED for all scores. For mSOFA, we used the first reported data, comprising 
the early resuscitation phase, as previously validated (18). For missing mSOFA values, we 
attributed a normal value (i.e., zero points), reflecting clinical practice and as widely reported 
(5, 8). In a sensitivity analysis, we used multiple imputation (5, 8). We also compared qSOFA 
and CRB with their corresponding qSOFA-65 and CRB-65, by adding the age component. 
 
Statistical Analysis 
 
 
We assessed the predictive performance of SIRS, qSOFA, CRB, mSOFA, CURB-65 
and PSI for the primary and secondary outcomes (19). We evaluated calibration with 
calibration plots and two complementary goodness-of-fit statistics (Hosmer-Lemeshow and 
the le Cessie-van Houwelingen-Copas-Hosmer tests) (20). Calibration curves were built with 
a smoothed non-parametric method (20, 21). We used the area under the receiver operating 
characteristic curve (AUROC) to assess discrimination. The 95% confidence interval (CI) 
estimation for the AUROCs and their comparisons were performed using bootstrapping 
methods in 10,000 samples (21, 22). Overall fit was assessed using scaled Brier score and 
Nagelkerke R-square (19, 21). To incorporate important information that clinicians might 
have at the bedside (8), we evaluated the additional predictive contribution of SIRS, qSOFA, 
CRB and mSOFA to a baseline risk for in-hospital mortality estimated by a multivariate 
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logistic regression model. The baseline risk model included age, gender, chronic respiratory 
disease, chronic neurologic disease, liver disease, heart failure, diabetes mellitus, neoplasia, 
chronic renal disease, and microbiologic confirmation. The baseline and additional risk 
models were fitted after multiple imputation. 
For a score to be clinically useful, it must have good discrimination and be well- 
calibrated but those alone are not enough (14, 23, 24). Indeed, discrimination and calibration 
may not reflect clinical utility (25). The main barrier to translating discrimination and 
calibration to clinical practice is that sensitivity, specificity and prediction errors are weighted 
equally (e.g., true-positive and false-positive rates), while clinicians usually apply different 
weights during the decision-making process (23). Decision-curve analysis is a method that 
depicts the predicted net benefit (“NB = benefit x true-positive classifications minus 
harm/cost x false-positive classifications”) of a prediction tool over a range of threshold 
probabilities. Threshold probabilities quantify how over-treatment is considered against 
treatment benefits (19, 23, 25-28). For instance, if a clinician weights the harm/cost of 
overtreatment versus the benefit of appropriated treatment at 1:19, we have a threshold 
probability of 5% and a number willing to treat (NWT) of 20 (26, 29). Decision curves have 
the advantage of being able to plot a plausible range of threshold probabilities. We defined 
100 to 5 NWTs as a plausible range (i.e., threshold probabilities from 0 to 20%), because it is 
unlikely that clinicians will use a score to make decisions about treatment of infected patients 
for higher threshold probabilities. At any given NWT, the score with the higher net benefit is 
the preferred one. The NB of each score was estimated for the primary and secondary 
outcomes and compared with the “treat-none” and “treat-all” strategies. The “treat-all” 
strategy assumes everyone will develop the event and receive the intervention independent of 
any score. The associated intervention comprises the initial treatment of septic patients in the 
ED, such as additional blood sampling, aggressive resuscitation, intensive monitoring, 
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invasive procedures, and, place of treatment. We hypothesized harm, at patient and hospital 
levels, associated with over-treatment and overuse of hospital resources, such as adverse 
events of broad-spectrum antibiotics and aggressive resuscitation/invasive procedures, ICU 
admission for patients unlikely to benefit and hospital costs (Figure 1) (4, 5, 30). Finally, we 
described the distribution and outcomes of patients based on combinations between SIRS 
(resembling Sepsis-2 definition), qSOFA (Sepsis-3 flowchart) and CRB with mSOFA. 
Sensitivity, specificity, positive and negative predictive values were calculated as 
shown elsewhere. As we expected few missing values for SIRS, qSOFA and CRB, our main 
analysis was conducted on the complete-case data; for sensitivity analysis, we conducted 
multiple imputation. We pre-specified two subgroups, defined by age (<65, ≥65yo), and 
chronic comorbidities (without chronic comorbidities, ≥1 chronic comorbidity). All statistical 
analyses were performed using R software, version 3.2.2 (R Foundation for Statistical 
Computing, Vienna, Austria) (31). We followed the TRIPOD guidelines (32) and further 
information about methods and statistical analysis are in the appendix. 
 
 
RESULTS 
 
 
Patient Characteristics 
 
 
The “Barcelona cohort” included 6,304 patients and the “Valencia cohort” 570 
patients, totaling 6,874 patients. The patients had a mean age of 66 (19) years, 62.2% were 
males and 65.5% presented ≥1 chronic comorbidity and 2,860 (41.8%) had microbiologic 
confirmation (Table 1). Seven hundred seventy-eight (11.3%) patients were discharged after 
a short-stay period in the ED, while 5,146 (74.9%) and 950 (13.8%) were admitted to the 
ward and ICU/HDU, respectively. Overall, in-hospital mortality occurred in 442 (6.4%) 
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patients, in-hospital mortality or ≥3 ICU/HDU days in 716 (10.4%) and, 30-day mortality in 
477/6,377 (7.5%) (Table 1). 
 
Scores distribution 
 
 
Our complete-case analysis comprised 6,024 patients (87.6%) (Table E2, Table E3, 
Figure E1). There was a clear association between qSOFA, CRB, mSOFA, CURB-65 and 
PSI with in-hospital mortality. Nevertheless, higher SIRS points poorly predicted in-hospital 
mortality (Figure 2). Similar results were found in the imputed data (Figure E2) and for 
secondary outcomes (Figure E3, Figure E4). 
Very few patients who were discharged after a short ED stay had qSOFA and CRB ≥2 
points (4 and 2%, respectively), whereas 61% had SIRS≥2 points (Figure 3). These patients 
had very low 30-day mortality (3/744, 0.4%). In contrast, patients admitted to the ICU/HDU 
had in-hospital mortality of 15.7%, and higher scores. Sepsis (Infection+mSOFA≥2 points) 
was present in 17% of patients discharged after a short ED stay, 64% of those admitted to the 
ward and 89% of patients treated in the ICU/HDU (Figure 3). 
Scores performance 
 
 
SIRS presented the lowest discrimination value (AUROC 0.579, 95% CI 0.551- 
0.605), followed by qSOFA (AUROC 0.697, 95% CI 0.671-0.722), CRB (AUROC 0.716, 
95% CI 0.690-0.741), CURB-65 (AUROC 0.746, 95% CI 0.722-0.769), mSOFA (AUROC 
 
0.748, 95% CI 0.721-0.774) and PSI (AUROC 0.780, 95% CI 0.760-0.799)(Table 2, Figure 
 
E5). All scores presented worse discrimination for in-hospital mortality in patients ≥65 years 
old. In those patients without chronic comorbidities, the discrimination of all scores improved 
(Table E4). Regarding calibration, in general scores overestimated in-hospital mortality, and 
mis-calibration was more evident for qSOFA, mSOFA and CURB-65 (Table 2, Figure E5). 
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The overall performance measured by the scaled Brier score and R-square increased from 
SIRS to qSOFA, CRB, CURB-65, mSOFA and PSI (Table 2). We observed similar results 
when analyzing Barcelona and Valencia cohorts separately, but mSOFA and CURB-65 had 
better discrimination in the Valencia cohort (Table E5). We found similar results when 
analyzing the imputed data (Table E6, Figure E6) and, for secondary outcomes (Table E7, 
Figure E7, Table E8, Figure E8). Nevertheless, for the composite outcome, CRB had better 
discrimination than qSOFA and mSOFA had the highest discrimination and best calibration. 
CRB-65 outperformed qSOFA, CRB and qSOFA-65 for in-hospital mortality (Table E9, 
Figure E9). 
Scores additional contribution to the baseline risk model 
 
 
When analyzing the predictive performance for in-hospital mortality in the multiple 
imputed data, SIRS contributed very little to the baseline model discrimination 
(AUROCBaseline 0.745, 95% CI 0.722-0.766 vs. AUROCBaseline+SIRS 0.752, 95% CI, 0.731- 
0.774). In contrast, qSOFA (AUROCBaseline+qSOFA 0.780, 95% CI, 0.760-0.800), CRB 
 
(AUROCBaseline+CRB 0.794, 95% CI, 0.775-0.813), and mSOFA (AUROCBaseline+mSOFA 0.836, 
 
95% CI, 0.818-0.854) notably improved the model discrimination. These improvements in 
discrimination were also observed in the IDI measures (Table E10, Figure E10). 
 
Clinical usefulness and decision-curve analysis 
 
 
Among the tools for the initial assessment, SIRS≥2 presented high sensitivity and low 
specificity, while qSOFA≥2 and CRB≥2 presented moderate sensitivity and high specificity 
for in-hospital mortality (Table 2). Among the follow-up tools, mSOFA≥2 presented high 
sensitivity and low specificity and CURB-65≥2 and PSI≥4 presented a good compromise 
between sensitivity (78 and 92%, respectively) and specificity (60 and 47%, respectively). 
CRB had the highest positive likelihood ratio (3.05, 95% CI, 2.65-3.51) and PSI the lowest 
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negative likelihood ratio (0.16, 95% CI, 0.12-0.23) (Table 2). We observed the same pattern 
in the imputed data (Table E6), and for secondary outcomes (Table E7, Table E8). In the 
sub-group analysis for in-hospital mortality, we observed similar findings except that 
mSOFA≥2 had higher specificity in the subgroup of patients aged<65 years (sensitivity 94, 
specificity 51%) and without chronic comorbidities (sensitivity 88, specificity 51%) (Table 
E11). 
The net benefit of qSOFA and CRB outperformed SIRS for in-hospital mortality, and 
SIRS showed a NB close to the “treat-all” strategy for the majority of the NWT values 
(Figure 4-A). For NWT between 15-30 and lower than 8, CRB had higher NB than qSOFA. 
PSI had the highest NB over the whole NWT range, except for values lower than 8, when 
mSOFA outperformed PSI for in-hospital mortality. When translating these findings to the 
number of avoided interventions in a hypothetical population of 100 patients with  
pneumonia, assuming a physician weights the harm/cost of overtreatment versus the benefit 
of appropriated treatment at 1:19 (NWT=20), the number of interventions could have been 
decreased by 7% without missing any death using SIRS; 16% using qSOFA; 27% using CRB 
or mSOFA; 30% using CURB-65 and 35% using PSI (Figure 4-B). We observed similar 
findings on NB for secondary outcomes, except that mSOFA outperformed other scores for a 
wide range of NWT for the composite outcome (Figure 4 C-D, Figure 4 E-F). The NB of 
the full models showed that “Baseline model+SIRS” had virtually no advantage compared 
with the “Baseline model” alone. The models “Baseline+qSOFA” and “Baseline+CRB” had 
higher NB than previous models for NWTs between 25 and 7. In contrast, the model 
“Baseline+mSOFA” presented the highest NB over the whole NWT range (Figure E11). 
Patients positive for SIRS/mSOFA (n=3,274, 54%) had 9.0% (95% CI, 8.5-9.5) in- 
hospital mortality, while those positive for qSOFA/mSOFA (n=1,090, 18%) and 
CRB/mSOFA (n=788, 13%) had 16.6% (95% CI, 15.5-17.7) and 18.0% (95% CI, 16.7-19.4) 
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in-hospital mortality, respectively (Figure 5). Similar findings were observed in the imputed 
data (Figure E12), and among patients with or without chronic comorbidities (Figure E13). 
 
 
DISCUSSION 
 
 
In a population of patients with community-acquired pneumonia, qSOFA 
outperformed SIRS for in-hospital mortality risk stratification and presented better clinical 
usefulness virtually in all evaluations. CRB had slightly better predictive performance than 
qSOFA for discrimination and calibration measures, but presented similar clinical usefulness 
for the majority of scenarios. For a comprehensive assessment of CAP, mSOFA and PSI had 
the best predictive performance and highest net benefit. The combination of qSOFA or CRB 
with mSOFA better selected high-risk patients, while potentially decreasing the burden of 
intensive monitoring and overtreatment. 
The Sepsis-2 definitions, published in 2001, raised awareness of sepsis syndrome and 
have been associated with better care and outcomes (6, 7). However, SIRS criteria weakly 
predicted patient outcomes (3, 33), which associated with its high sensitivity and low 
specificity, likely classify SIRS as an unreliable tool for bedside clinical decision-making, 
and research (5, 8, 34, 35). Our current analysis in CAP patients confirmed these limitations 
(3) and highlighted risks of overtreatment, demonstrating that the NB of SIRS is comparable 
to the “treat-all” strategy. Indeed, the decision-curve analysis showed that when different 
weights for true-positive and false-positive classifications were applied, SIRS did not provide 
any additional benefit for decision-making. In contrast, we found a positive NB if clinicians 
incorporated qSOFA or CRB for the initial assessment, decreasing the number of  
unnecessary interventions while not missing any death. qSOFA and CRB were better than 
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SIRS or a “treat-all” strategy for NWT values below 40, which seems reasonable for use in 
the ED (5, 30), where qSOFA and CRB can be easily assessed. Given that CRB and CRB-65 
were specifically developed for CAP patients, they had better calibration and discrimination 
than qSOFA, as well as higher specificity. Thus, rather than qSOFA, physicians could 
consider CRB or CRB-65 for the initial risk stratification of CAP patients. 
For a comprehensive assessment of CAP, PSI had the best mortality prediction and 
highest NB from high NWT values down to an NWT of 8, reinforcing its pivotal role on CAP 
management. mSOFA seemed to be more applicable for NWT values below 12, mainly when 
considering ICU admission. This might be because PSI comprises 20 variables and has age as 
a main determinant for risk classification; while mSOFA measures acute organ dysfunctions 
in 6 domains. Further studies should investigate whether both scores are complementary in 
CAP management. Of note, the Baseline+mSOFA model, which could be analogous to 
PSI+mSOFA, had higher discrimination and NB than PSI alone. 
Our results are in line with those of the pivotal Sepsis-3 clinical criteria study (5, 8), 
which showed better discrimination for qSOFA and mSOFA compared with SIRS. In 
contrast, mSOFA clearly outperformed qSOFA in our population. The discrimination of 
qSOFA in our study was lower than that reported originally in Sepsis-3 (5), which might be 
because of the differences in the populations included and because we measured qSOFA and 
mSOFA using ED data. Sepsis-3 aimed to identify infected patients with ≥10% of mortality 
(5, 8, 36). In our study that goal was achieved: 18% of the patients presented positive 
qSOFA/mSOFA and in-hospital mortality in these patients was 16.6%. Interestingly, when 
describing the prevalence of each score categorized by place of treatment, it seems that 
clinicians relied on the parameters hypotension, altered mental status and tachypnea for 
decision-making. Indeed, only 2% and 4% of patients who were not hospitalized had 
qSOFA≥2 and CRB≥2, respectively. However, SIRS≥2 was present in the vast majority of 
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the promptly discharged patients (61%). Interestingly, 46% of patients had 
qSOFA<2/mSOFA≥2; in-hospital mortality in these patients was low (5.4%); this might 
indicate that patients with qSOFA<2 presented some points on mSOFA, but ultimately not 
associated with death. Among the scores we evaluated, qSOFA was recently developed by a 
data-driven process from large databases. As with CRB, it attributes one point to each clinical 
parameter, is promptly available at bedside and is easily repeated without invasive measures. 
Yet it is important to emphasize that the suggested cut-off of 2 points for qSOFA had low 
sensitivity, being inappropriate if applied as a single screening tool, resulting in delayed 
recognition of sepsis (37). 
Our study has some strengths that must be highlighted. First, we described challenges 
in decision-making that could be faced by clinicians on a daily basis, not only during 
evaluation of hospitalized patients, but also in those rapidly discharged following ED 
evaluation. Additionally, it is known that predictive performance measures have 
disadvantages (19-21, 32, 38) and are difficult to translate into clinical-practice (14). Thus, 
we used clinical decision-making analyses (13) to complement predictive performance 
evaluations, which are fundamental to better support clinicians’ decision (23, 24, 39). 
This study has also some limitations. First, we analyzed one type of infection, from 
only two Spanish institutions, potentially limiting generalizability of our results. However the 
data came from two prospective CAP cohorts, increasing our ability to capture data 
granularity. Second, although our data were prospective collected from consecutive patients 
and had few missing values, misclassification and selection bias could have occurred. We 
expect both to be low, due to the standard procedures for prospective data collection and 
researchers’ extensive expertise in this field. Moreover, our outcomes were objective 
(mortality/ICU admission) and we had few losses to follow-up, decreasing the possibility of 
outcome bias. Third, we could not fully calculate the SOFA score for the cardiovascular and 
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neurological parameters; thus, by adopting a conservative approach we may have hampered 
the SOFA performance. However, the mSOFA score maintained its high predictive power, 
confirming feasibility of SOFA score calculation outside the ICU (18). Fourth, we could not 
differentiate between acute and chronic organ dysfunction; however, our analysis excluding 
patients with chronic comorbidities showed similar findings. Fifth, we observed score mis- 
calibration, which can influence clinical decision based on NB (40). Finally, we did not 
incorporate clinical judgment into the models, which could ultimately improve the 
performance of the Sepsis-3 flowchart. 
 
CONCLUSIONS 
 
 
We demonstrated that for initial assessment, qSOFA outperformed SIRS and 
presented better clinical usefulness in CAP patients in the ED. Moreover, CRB and CRB-65 
had better predictive performance than qSOFA for initial stratification of CAP patients in 
some scenarios, including higher net benefit for some values of NWT. For the comprehensive 
assessment of CAP, PSI had the best predictive performance and net benefit for mortality, 
while mSOFA seemed more suitable when considering ICU admission. Finally, the Sepsis-3 
flowchart provided an improved, feasible approach for identifying patients with CAP at 
higher risk of death. Further studies, including other CAP cohorts and other sources of 
infection, should be conducted to corroborate our findings. 
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FIGURE LEGENDS: 
 
 
 
Figure 1. Flowchart about the decision-making process for community-acquired 
pneumonia management at the emergency department 
 
*First clinical decision encompasses the decision to assess organ dysfunction and pneumonia 
severity with additional laboratory and/or invasive procedures 
 
†Second clinical decision encompasses the decision, after full assessment, to admit the 
patient to the ward/ICU, consider additional treatment not yet started or change treatments 
already started 
 
The flowchart does not regulate timing for institute life-saving treatments or, for instance, 
prompt starting of empiric antibiotic treatment. 
 
 
 
 
 
Figure 2. In-hospital mortality stratified by each score in patients with community- 
acquired pneumonia 
 
Panel A: systemic inflammatory response syndrome (SIRS) criteria; Panel B: quick 
Sequential (Sepsis-related) Organ Failure; Panel C: Confusion, Respiratory rate and Blood 
pressure (CRB) points; Panel D: modified Sequential (Sepsis-related) Organ Failure 
Assessment (SOFA) points; Panel E: Confusion, Urea, Respiratory rate, Blood pressure and 
Age (CURB-65) points and Panel F: Pneumonia Severity Index (PSI) risk class. 
Error bars denote 95% confidence intervals. The x-axis for mSOFA score was winsorized for 
values higher than 7 points for illustration. 
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Figure 3. Distribution of SIRS, qSOFA, CRB, mSOFA, CURB-65 and PSI scores, place 
of treatment and mortality for community-acquired pneumonia patients. 
 
CAP – community-acquired pneumonia; CRB - Confusion, Respiratory rate and Blood 
pressure; CURB-65 – Confusion, Urea, Respiratory rate, Blood pressure and Age; ED – 
emergency department; HDU – high-dependency unit; ICU – intensive care unit; NWT – 
number willing to treat; qSOFA – quick Sequential (Sepsis-related) Organ Failure 
Assessment; SIRS – systemic inflammatory response syndrome; mSOFA – modified 
Sequential (Sepsis-related) Organ Failure Assessment; PSI – Pneumonia Severity Index. 
* Patients were followed up until hospital discharge, and all survivors were re-examined or 
contacted by phone 30 days after hospital discharge. 
 
 
 
Figure 4. Decision curves showing the net benefit of SIRS criteria, qSOFA, CRB, 
mSOFA, CURB-65 and PSI scores in the treatment of community-acquired pneumonia 
patients at risk of in-hospital mortality, composite outcome and 30-day mortality. 
Panels A, C and E show the net benefit (NB = benefit x true-positive classifications minus 
harm/cost x false-positive classifications) of each score and the strategy to treat-none and 
treat-all patients over the plausible range of number willing to treat (NWT) (i.e., threshold 
probabilities). Panels B, D and F show the net reduction in interventions in a theoretical 
population of 100 patients by using the scores to make clinical decisions. 
Illustrative example: if a clinician weights the harm/cost of overtreatment versus the benefit 
of appropriated treatment at 1:19 for in-hospital mortality, we have a threshold probability of 
5% and a NWT of 20. This choice specifies that death of a community-acquired pneumonia 
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patient who remained untreated is 19 times worse than the consequences of overtreatment of 
an unnecessarily-treated patient. At a NWT of 19, the net benefit of the SOFA, qSOFA and 
CRB scores outperform SIRS and, treat-all strategies. At the same time, at a NWT of 20, we 
could reduce the number of interventions without missing any in-hospital death by 7% using 
SIRS criteria, 16% using qSOFA, 27% using CRB or mSOFA scores, 30% for CURB-65 and 
35% for PSI. 
CRB – Confusion, Respiratory rate and Blood pressure; CURB-65 – Confusion, Urea, 
Respiratory rate, Blood pressure and Age; NWT – number willing to treat; qSOFA – quick 
Sequential (Sepsis-related) Organ Failure Assessment; SIRS – systemic inflammatory 
response syndrome; mSOFA – modified Sequential (Sepsis-related) Organ Failure 
Assessment; PSI – Pneumonia Severity Index. 
 
 
 
 
 
Figure 5. In-hospital mortality of 6,024 patients with community-acquired pneumonia, 
stratified by SIRS, qSOFA or CRB combined with mSOFA. Panel A shows the in- 
hospital mortality stratified by SIRS criteria and mSOFA scores combinations. Panel B 
shows the in-hospital mortality stratified by qSOFA and mSOFA scores combinations. Panel 
C shows the in-hospital mortality stratified by CRB and mSOFA scores combinations. Error 
bars denote 95% confidence interval. The numbers and percentages between parentheses 
represent the frequency distribution of each combination in the whole cohort. 
 
 
CRB - Confusion, Respiratory rate and Blood pressure; qSOFA – quick Sequential (Sepsis- 
related) Organ Failure Assessment; SIRS – systemic inflammatory response syndrome; 
mSOFA – modified Sequential (Sepsis-related) Organ Failure Assessment. 
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Table 1 – Characteristics of community-acquired patients from two cohorts in Spain 
 Overall (n=6,874) 
Demographic variables, n(%) or mean (SD)  
Age, years 66.1 (19) 
Age ≥65 years 4,170 (60.9%) 
Gender Male 4,259 (62.2%) 
Co-morbidities, n (%)  
Chronic respiratory disease 2,045 (30.3%) 
Chronic heart failure 1,127 (16.5%) 
Diabetes mellitus 1,299 (19.1%) 
Chronic liver disease 371 (5.6%) 
Chronic renal disease 499 (7.3%) 
Neurologic disease 1,135 (17.0%) 
Neoplasia 489 (7.3%) 
Nursing home 361 (5.3%) 
Vital signs upon presentation, mean (SD)  
Respiratory rate, per min 26 (8) 
Heart rate, beats per min 98 (19) 
Systolic blood pressure, mmHg 131 (27) 
Diastolic blood pressure, mmHg 73 (14) 
Mean arterial pressure, mmHg 92 (16) 
Temperature °C 37.5 (1) 
Laboratory findings upon presentation, median [IQR] or n (%)  
Leukocyte, cells/mm3 12,400 [8,570-17,280] 
C-reactive protein, mg/dl 16.7 [7.8-26.3] 
Creatinine, mg/dl 1.0 [0.8-1.4] 
Total bilirubin, mg/dl 0.50 [0.40-0.80] 
Platelets, cells/mm3 234 [187-302] 
PaO2/FiO2 ratio, mmHg 281 [238-328] 
Microbiology confirmed 2,860 (41.8%) 
Scores upon diagnosis, mean (SD) / median [IQR]  
SIRS, points 2.3 (1) / 2 [2-3] 
SIRS ≥ 2 4,908 (78.8%) 
qSOFA, points 1.0 (0.7) / 1 [0-1] 
qSOFA ≥ 2 1,260 (20.5%) 
CRB, points 0.7 (0.8) / 1 [0-1] 
CRB ≥ 2 902 (14.6%) 
mSOFA, points 2.2 (2) / 2 [1-3] 
mSOFA ≥ 2 4,288 (62.4%) 
CURB-65, points 1.4 (1) / 1 [1-2] 
CURB ≥ 2 2,592 (42.0%) 
PSI, points 3.4 (1) / 4 [2-4] 
PSI ≥ 4 3,379 (55.4%) 
Outcomes, n (%) or median [IQR]  
In-hospital mortality 442 (6.4%) 
In-hospital mortality or 3 days of ICU stay 716 (10.4%) 
30-days mortality 477/6,377 (7.5%) 
Hospital stay, days 7 [4-10] 
Abbreviations: CRB: Confusion, Respiratory rate and Blood pressure; CURB-65: Confusion, Urea, Respiratory rate , Blood pressure and Age; 
ICU: intensive care unit; mSOFA: modified Sequential (Sepsis-related) Organ Failure Assessment; PSI: Pneumonia Severity Index; qSOFA: 
quick Sequential (Sepsis-related) Organ Failure Assessment; SIRS: systemic inflammatory response syndrome. 
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Table 2. Scores performance and clinical utility for in-hospital mortality in 6,024 patients with community-acquired pneumonia (complete-case analysis) 
 
 
Discrimination 
 
Calibration 
 
Overall performance 
 
Clinical utilit
 
y 
 
Score 
 
AUROC 
(95% CI) 
Hosmer- Global 
Lemeshow calibration
test test* 
Scaled 
Brier 
score 
 
Nagelkerke R-
square 
 
Score category  
Sensitivity Specificity 
(95% CI) (95% CI) 
 
PPV 
(95% CI) 
 
NPV 
(95% CI) 
 
LR+ 
(95% CI) 
 
LR- 
(95% CI) 
 
SIRS 
 
0.579 (0.551*0.605) 
 
0.776 
 
0.061 
 
0.9% 
 
1.3% 
 
SIRS≥2 
 
89 (85-92) 
 
22 (20-23) 
 
7 (6-8) 
 
97 (96-98) 
 
1.13 (1.09-1.18) 
 
0.52 (0.39-0.69) 
 
qSOFA 
 
0.697 (0.671-0.722) 
 
0.494 
 
0.036 
 
4.3% 
 
8.8% 
 
qSOFA≥2 
 
50 (45-55) 
 
81 (80-82) 
 
15 (13-17) 
 
96 (96-97) 
 
2.70 (2.41-3.03) 
 
0.61 (0.55-0.68) 
 
CRB 
 
0.716 (0.690-0.741) 
 
0.997 
 
0.224 
 
4.3% 
 
10.7% 
 
CRB≥2 
 
40 (35-45) 
 
87 (86-88) 
 
17 (14-20) 
 
96 (95-96) 
 
3.05 (2.65-3.51) 
 
0.69 (0.64-0.75) 
 
mSOFA 
 
0.748 (0.721-0.774) 
 
0.999 
 
0.040 
 
7.7% 
 
14.3% 
 
mSOFA≥2 
 
88 (85-91) 
 
37 (36-38) 
 
9 (8-9) 
 
98 (97-99) 
 
1.41 (1.35-1.47) 
 
0.31 (0.24-0.42) 
 
CURB-65 
 
0.746 (0.722-0.769) 
 
0.801 
 
0.008 
 
5.9% 
 
12.9% 
 
CURB-65≥2 
 
78 (74-82) 
 
60 (59-61) 
 
12 (10-13) 
 
98 (97-98) 
 
1.96 (1.84-2.09) 
 
0.36 (0.30-0.44) 
 
PSI 
 
0.780 (0.760-0.799) 
 
0.998 
 
0.221 
 
7.8% 
 
17.4% 
 
PSI ≥4 
 
92 (89-95) 
 
47 (46-48) 
 
10 (09-11) 
 
99 (98-99) 
 
1.74 (1.68-1.81) 
 
0.16 (0.12-0.23) 
 
AUROC 
curve 
SIRS vs: qSOFA (p<0.001), CRB (p<0.001), mSOFA (p<0.001), CURB-65 (p<0.001), PSI (p<0.001) 
qSOFA vs: CRB (p=0.055), mSOFA (p=0.001), CURB-65 (p<0.001), PSI (p<0.001) 
CRB vs: mSOFA (p=0.035), CURB-65 (p<0.001), PSI (p<0.001) 
comparisons:  mSOFA vs: CURB-65 (p=0.924), PSI (p=0.031) 
CURB-65 vs: PSI (p=0.002) 
 
 
 
 
 
AUROC: area under the receiver operating characteristic curve; CI: confidence interval; CRB: Confusion, Respiratory rate and Blood pressure; CURB-65: Confusion, Urea, 
Respiratory rate, Blood pressure and Age; LR+: positive likelihood ratio; LR-: negative likelihood ratio; mSOFA: modified Sequential (Sepsis-related) Organ Failure 
Assessment; NPV: negative predictive value; PSI: Pneumonia Severity Index; qSOFA: quick Sequential (Sepsis-related) Organ Failure Assessment; PPV: positive 
predictive value; SIRS: systemic inflammatory response syndrome;. * le Cessie-van Houwelingen-Copas-Hosmer test. 
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6,874 patients with 
CAP diagnosed  
in the ED 
778 (11%) patients 
discharged after 
ED short-stay 
5,146 (75%) 
patients admitted  
to the ward 
950 (14%) 
patients admitted 
to the ICU/HDU 
Score category Prevalence 
SIRS ≥ 2  61% 
qSOFA ≥ 2  04% 
CRB ≥ 2  02% 
mSOFA ≥ 2 17% 
CURB-65 ≥ 2  08% 
PSI ≥ 4 12% 
Score category Prevalence 
SIRS ≥ 2  79% 
qSOFA ≥ 2  19% 
CRB ≥ 2  13% 
mSOFA ≥ 2 64% 
CURB-65 ≥ 2  44% 
PSI ≥ 4 59% 
Score category Prevalence 
SIRS ≥ 2  91% 
qSOFA ≥ 2  41% 
CRB ≥ 2  32% 
mSOFA ≥ 2 89% 
CURB-65 ≥ 2  58% 
PSI ≥ 4 72% 
 
30-day mortality: 
3/744 (0.4%)* 
 
 
30-day mortality: 
323/4,731 (6.8%)* 
 
30-day mortality: 
151/902 (16.7%)* 
In-hospital mortality: 
0/778 (0%) 
In-hospital mortality: 
293/5,146 (5.7%) 
In-hospital mortality: 
149/950 (15.7%) 
34 were lost to 
follow-up 
415  were lost to 
follow-up 
48 were lost to 
follow-up 
Figure 3 
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Table E1. SIRS criteria, qSOFA, qSOFA-65, CRB, CRB-65, mSOFA, CURB-65 and PSI 
definitions 
 
Table E1 - A: SIRS criteria definition 
 
 SIRS(1) Points 
Temperature >38°C or <36°C 1 point 
Heart rate >90/min 1 point 
Respiratory rate or PaCO2 
>20/min or PaCO2 <32 
mm Hg 1 point 
White blood cell count 
>12.000/mm3 or 
<4.000/mm3 or 10% 
immature bands 
1 point 
 
Table E1 - B: qSOFA, qSOFA-65, CRB and CRB-65 scores definition 
 
 qSOFA(2) qSOFA-65(3) CRB(4, 5) CRB-65(5, 6) Points 
Respiratory rate ≥22/min ≥22/min ≥30/min ≥30/min 1 point 
Altered mentation Presence Presence Presence Presence 1 point 
Hemodynamic 
status 
Systolic blood  
pressure ≤100 
mm Hg 
Systolic blood  
pressure ≤100 
mm Hg 
Systolic blood 
pressure <90 mm Hg 
or Diastolic blood 
pressure ≤ 60 mm Hg 
Systolic blood 
pressure <90 mm Hg 
or Diastolic blood 
pressure ≤ 60 mm Hg 
1 point 
Age - ≥ 65 - ≥ 65 1 point 
 
Page 33 of 60  AJRCCM Articles in Press. Published on 14-June-2017 as 10.1164/rccm.201611-2262OC 
 Copyright © 2017 by the American Thoracic Society 
3 
 
Table E1 - C:  modified SOFA score(2, 7-9) 
 Original Definition Barcelona cohort definition 
Valencia 
cohort definition 
Respiratory 
Points PaO2/FiO2 (mmHg) PaO2/FiO2 (mmHg) PaO2/FiO2 (mmHg) 
0 ≥400 ≥400 ≥400 
1 300-399 300-399 300-399 
2 200-299 200-299 200-299 
3 100-199 and Respiratory support 100-199 and Respiratory support 100-199 and Respiratory support 
4 <100 and Respiratory Support <100 and Respiratory Support <100 and Respiratory Support 
Hematologic 
Points Platelets count (x103/mm3) Platelets count (x103/mm3) Platelets count (x103/mm3) 
0 ≥150 ≥150 ≥150 
1 100-149 100-149 100-149 
2 50-99 50-99 50-99 
3 20-49 20-49 20-49 
4 <20 <20 <20 
Hepatic 
Points Total serum Bilirubin mg/dl Total serum Bilirubin mg/dl Total serum Bilirubin mg/dl 
0 <1.2 <1.2 <1.2 
1 1.2-1.9 1.2-1.9 1.2-1.9 
2 2.0-5.9 2.0-5.9 2.0-5.9 
3 6.0-11.9 6.0-11.9 6.0-11.9 
4 >12.0 >12.0 >12.0 
Cardiovascular 
Points MAP or vasoactive drugs 
MAP 
or shock status 
MAP 
or shock status 
0 ≥ 70 mmHg ≥ 70 mmHg ≥ 70 mmHg 
1 < 70 mmHg < 70 mmHg < 70 mmHg 
2 Dopamine <5 or Dobutamine (any dose) 
Refractory hypotension attributed to infection 
after adequate fluid resuscitation  
and use of any vasopressor 
Refractory hypotension attributed to 
infection after adequate fluid resuscitation 
and use of  any vasopressor 
3 Dopamine 5.1 -15 or Epinephrine ≤0.1 or Norepinephrine ≤0.1 - - 
4 Dopamine >15 or Epinephrine >0.1 or Norepinephrine >0.1 - - 
Neurologic 
Points Glasgow Coma Scale Mental status Mental status 
0 15 Normal Normal 
1 13-14 Acute altered mental status  (confusion, decreased consciousness) 
Acute altered mental status  
(confusion, decreased consciousness) 
2 10-12 - - 
3 6-9 - - 
4 <6 - - 
Renal 
Points Creatinine (mg/dL) or Urinary Output (mL) Creatinine (mg/dL) 
Creatinine (mg/dL) or Urinary Output 
(mL) 
0 sCr <1.2 sCr <1.2 sCr <1.2 
1 sCr 1.2-1.9 sCr 1.2-1.9 sCr 1.2-1.9 
2 sCr 2.0-3.4 sCr 2.0-3.4 sCr 2.0-3.4 
3 sCr 3.5-4.9 or UO<500 ml/24h sCr 3.5-4.9 sCr 3.5-4.9 or UO <0.5 ml/Kg/h for 2h 
4 sCr ≥5.0 or UO≤ 200ml/24h sCr ≥5.0 sCr ≥5.0 
sCR – serum creatinine; UO – urinary output  
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Table E1 - D: CURB-65 score definition 
 
 CURB-65(4) Points 
Respiratory rate ≥30/min 1 point 
Altered mentation Presence 1 point 
Hemodynamic status Systolic blood pressure <90 mm Hg or Diastolic blood pressure ≤ 60 mm Hg 1 point 
Age ≥65 years 1 point 
Urea >7 mmol/l 1 point 
 
 
Table E1 - E: PSI score definition(10) 
 
 
  Points 
Age > 50 years No 
No for all: 
PSI risk class I 
 
Neoplastic disease No 
Liver disease No 
Congestive heart failure No 
Cerebrovascular disease No 
Renal disease No 
Altered mental status No 
Respiratory rate ≥ 30 breaths/minute No 
Systolic blood pressure < 90 mm Hg No 
Temperature <30º or ≥ 40ºC No 
Pulse ≥ 125 beats/minute No 
If yes for some condition above: 
Age Male Age (yr) 
 Female Age - 10 
Nursing home resident Yes +10 
Neoplastic disease Yes +30 
Liver disease Yes +20 
Congestive heart failure Yes +10 
Cerebrovascular disease Yes +10 
Renal disease Yes +10 
Altered mental status Yes +20 
Respiratory rate ≥ 30 breaths/minute Yes +20 
Systolic blood pressure < 90 mm Hg Yes +20 
Temperature <30º or ≥ 40ºC Yes +15 
Pulse ≥ 125 beats/minute Yes +10 
Arterial pH < 7.35 Yes +30 
BUN ≥ 11 mmol/L Yes +20 
Sodium <130 mmol/L Yes +20 
Glucose ≥ 250 mg/dL (14 mmol/L) Yes +10 
Hematocrit < 30% Yes +10 
PaO2 < 60 mm Hg or oxygen 
saturation <90% on pulse oximetry Yes +10 
Pleural effusion Yes +10 
 
Risk class II: ≤70 points,  
Risk class III: 71-90 points;  
Risk class IV: 91-130 points;  
Risk class V: >130 points  
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Additional description of statistical methods 
 
We performed all analysis in a merged dataset as a whole cohort, because the cohorts were from two research groups 
with intense collaboration, having similar standardized definitions and methods of data collection. Before merging, we 
re-checked definitions, implausible values and standardized each variable.  
 
Scores performance: Predictive performance measures had advantages and disadvantages(11-15); to overcome this 
problem we explored different and complementary methods. Calibration was mainly evaluated by Calibration plots. 
Calibration curves were built with a smoothed nonparametric method(13, 15). We also evaluated two complementary 
goodness-of-fit statistics to assess calibration (Hosmer-Lemeshow and the le Cessie-van Houwelingen-Copas-Hosmer 
tests)(15). We used two goodness-of-fit statistics because the Hosmer-Lemeshow test divides the population in 10 
groups, which is an arbitrary cut-off, as well it is sensible to the sample size (14, 16). We used the area under the 
receiver-operating characteristic curve (AUROC) to assess discrimination. The 95% confidence interval (CI) estimation 
for the AUROCs and theirs comparisons were performed using bootstrapping method in 10,000 samples (13, 17). We 
assessed overall fit using two measures: 1) scaled Brier score (mean squared error between the outcome and prediction; 
Brier score was scaled on its maximum value for an interpretation similar to the r-square), and 2) Nagelkerke R-square 
(13, 14). For better comparison of the additional prediction contribution of each score to the baseline risk model, we 
used the integrated discrimination improvement (IDI) index (13, 14). Net reclassification measures were not used 
because there is not an established cut-off risk for mortality in septic patients. 
 
Baseline risk model: after multiple imputation of 10 datasets, we fit a multivariate logistic model. In-hospital mortality 
was the dependent variable and age, gender, chronic respiratory disease, chronic neurologic disease, liver disease, heart 
failure, diabetes mellitus, neoplasia, chronic renal disease, and etiologic diagnosis. Age was modeled through a 
restricted cubic spline. 
 
Multiple imputation: As we expected few missing values for SIRS, qSOFA and CRB, our main analysis was conducted 
in the complete-case data (i.e., patients for whom we had all data for the SIRS, qSOFA and, CRB). We investigated the 
missing data patterns for covariates and scores, and we assumed missing at random (MAR) conditioned in the 
covariates (18). We used multiple imputation (aregImpute routine)(14) to generate 10 datasets to evaluate the prediction 
performance for the primary outcome (in-hospital mortality). The model for multiple imputation included all covariates 
of the baseline risk model, and the SIRS, qSOFA, CRB, SOFA, CURB-65 and PSI variables. As recommended, the 
model also included the outcome (in-hospital mortality), and the cohort indicator (“Barcelona”/ “Valencia”) as an 
auxiliary variable. For simplicity, we filled in missing values with the first set of imputed values from the multiple 
imputation for the predictive performance evaluation (14, 19).  
 
The original scores and those constructed after multiple imputation followed a normal distribution for SIRS and non-
normal for qSOFA, CRB, CURB-65 and PSI. 
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Decision-curve analysis 
A well-calibrated score is necessary but not enough for clinical usefulness, as well good discrimination (20, 21). To 
support clinical decision making, the above statistical measures may not reflect clinical utility (Can I make better 
decisions by using a score than without it?).(22) The main difficult to translate discrimination and calibration to clinical 
practice is because they equally weight sensitivity, specificity and prediction errors (e.g., true-positive and false-positive 
rates).(20) Nevertheless, in clinical practice, clinicians usually apply different weights during the decision-making 
process; furthermore, the weights depend on the patient characteristics and resources availability (20). Decision-curve 
analysis was recently introduced in clinical research and depicts the predicted net benefit (“NB = benefit x true-positive 
classifications minus harm/cost x false-positive classifications”) of a prediction tool over a range of threshold 
probabilities. Threshold probabilities quantify how overtreatment is considered against treatment benefits (14, 20, 22-
25). For instance, whether a clinician weights the harm/cost of overtreatment versus the benefit of appropriated 
treatment (e.g., early antibiotic, aggressive resuscitation and intensive monitoring) at 1:19, we have a threshold 
probability of 5% and a number willing to treat (NWT) of 20.(23, 26) Thus, the 5% threshold probability specifies that 
death of a septic patient who remained untreated is 19 times worse than the consequences of overtreatment of an 
unnecessarily treated patient.(26) There is not an established cut-off risk for treating sepsis; and decision-curves have 
the advantage to plot a plausible range of threshold probabilities. We defined 100 to 5 NWTs as plausible range (i.e., 
threshold probabilities from 0 to 20%), because it is unlikely clinicians will use a score to make decisions about 
treatment of septic patients for higher threshold probabilities. 
It is worth noting that decision-curve analysis cannot be used to choose a threshold probability (20, 27). Second, 
prediction tools with higher NB perform better than other at that risk threshold, independently by how much it is higher 
(20, 27). Third, decision-curve interpretation also varies according to the outcome prevalence (27). As expected, for 
common outcomes, the NB of treat-all strategy is higher than when the outcome occurrence is low. The NB is higher as 
the risk model identifies high-risk patients without classifying patients without the event as high-risk patients (27). 
  
All statistical analyses were performed using R software, version 3.2.2 (R Foundation for Statistical Computing, 
Vienna, Austria)(28), with the adds-on packages: rms, Hmisc, epiR, foreign, pROC, sciplot and the function dca 
(available at https://www.mskcc.org/departments/epidemiology-biostatistics/health-outcomes/decision-curve-analysis-
01).  
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Table E2. SIRS, qSOFA, CRB, mSOFA, CURB-65 and PSI distribution among cohorts 
 
 Overall Barcelona Missing 
values 
Valencia Missing values 
SIRS   626 (9.9%)  18 (3.2%) 
0 284 (4.6%) 235 (4.1%)  49 (8.9%)  
1 1038 (16.7%) 903 (15.9%)  135 (24.5%)  
2 2058 (33.0%) 1859 (32.7%)  199 (36.1%)  
3 2035 (32.7%) 1903 (33.5%)  132 (29.3%)  
4 815 (13.1%) 778 (13.7%)  37 (6.7%)  
qSOFA   696 (11.0%)  17 (3.0%) 
0 1590 (25.8%) 1251 (22.3%)  339 (61.3%)  
1 3311 (53.7%) 3129 (55.8%)  182 (32.9%)  
2 1102 (17.9%) 1076 (19.2%)  26 (4.7%)  
3 158 (2.6%) 152 (2.7%)  6 (1.1%)  
CRB   696 (11.0%)  17 (3.0%) 
0 3029 (49.2%) 2631 (46.9%)  398 (72.0%)  
1 2230 (36.2%) 2105 (37.5%)  125 (22.6%)  
2 756 (12.2%) 727 (13.0%)  29 (5.2%)  
3 146 (2.4%) 145 (2.6%)  1 (0.2%)  
mSOFA*   -  - 
0 1269 (18.5%) 1142 (18.1%)  127 (22.3%)  
1 1317 (19.2%) 1220 (19.4%)  97 (17.0%)  
2 1847 (26.9%) 1691 (26.8%)  156 (27.4%)  
3 1116 (16.2%) 1028 (16.3%)  88 (15.4%)  
4 657 (9.5%) 622 (9.9%)  35 (6.1%)  
5 293 (4.3%) 272 (4.3%)  21 (3.7%)  
6 190 (2.8%) 165 (2.6%)  25 (4.4%)  
>=7 185 (2.7%) 164 (2.6%)  21 (3.7%)  
CURB-65   707 (11.2%)  17 (3.0%) 
0 1,351 (22.0%) 1,217 (21.7%)  134 (24.2%)  
1 2,211 (36.0%) 1,973 (35.3%)  238 (43.0%)  
2 1,625 (26.4%) 1,500 (26.8%)  125 (22.6%)  
3 720 (11.7%) 677 (12.1%)  43 (7.8%)  
4 208 (3.4%) 195 (3.5%)  13 (2.4%)  
5 35 (0.6%) 35 (0.6%)  -  
PSI   756 (12.0%)  17 (3.0%) 
Class Risk I 807 (13.2%) 733 (13.2%)  74 (13.4%)  
Class Risk II 831 (13.6%) 724 (13.1%)  107 (19.4%)  
Class Risk III 1,084 (17.8%) 934 (16.8%)  150 (27.1%)  
Class Risk IV 2,065 (33.9%) 1,893 (34.1%)  172 (31.1%)  
Class Risk V 1,314 (21.5%) 1,264 (22.8%)  50 (9.0%)  
* Normal range (0 points) was imputed for missing values in mSOFA 
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Table E3. mSOFA score missing pattern and mSOFA distribution 
 
Table E3 - A: mSOFA score missing pattern 
Missing systems for mSOFA General 
No missing 1978 (28.8%) 
1 system missing 2829 (41.2%) 
2 system missing 1708 (24.9%) 
3 system missing 260 (3.8%) 
4 system missing 54 (0.8%) 
5 system missing 20 (0.3%) 
6 system missing 25 (0.4%) 
We adapted the components for Cardiovascular, Neurological and Renal components. 
 
Table E3 - B: mSOFA distribution originally and after imputation 
mSOFA score Overall Barcelona Valencia 
6 systems available (n=1,978)    
Mean (SD) 
 
2.8 (2) 
 
2.8 (2) 
 
3.2 (2) 
 
Median [IQR] 2 [2-4] 2 [2-4] 2 [2-4] 
Simple imputation* 
(0 values for systems with missing) 
   
Mean (SD) 
 
2.2 (2) 
 
2.2 (2) 
 
2.2 (2) 
 
Median [IQR] 2 [1-3] 2 [1-3] 2 [1-3] 
Multiple imputation 
 
   
Mean (SD) 
 
2.7 (2) 2.7 2.8 
Median [IQR] 2 [2-4] 2 [2-4] 2 [2-3] 
  * Missing values imputed as zero(7)  
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Figure E1. Distribution of scores in 6,024 patients with community-acquired pneumonia. 
Panel A: systemic inflammatory response syndrome (SIRS) criteria; Panel B: quick Sequential (Sepsis-related); Panel C: Confusion, Respiratory rate and Blood pressure (CRB) points; 
Panel D: modified Sequential (Sepsis-related) Organ Failure Assessment (mSOFA) points; Panel E: Confusion, Urea, Respiratory rate, Blood pressure and Age (CURB-65) points and 
Panel F: Pneumonia Severity Index (PSI) risk class.   
Error bars denote 95% confidence intervals. The x-axis for mSOFA score was winsorized for values higher than 7 points for illustration.   
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Figure E2. Distribution of scores and in-hospital mortality stratified by score points in 6,874 patients with 
community-acquired pneumonia (imputed data) 
Panels A, B, C, D, E and F: scores distribution for systemic inflammatory response syndrome (SIRS) criteria; quick Sequential (Sepsis-related); Respiratory rate and Blood 
pressure (CRB), modified Sequential (Sepsis-related) Organ Failure Assessment (mSOFA); Confusion, Urea, Respiratory rate, Blood pressure and Age (CURB-65) and 
Pneumonia Severity Index (PSI). Panels G, H, I, J, K and L: in-hospital mortality stratified by systemic inflammatory response syndrome (SIRS) criteria; quick Sequential 
(Sepsis-related); Respiratory rate and Blood pressure (CRB), modified Sequential (Sepsis-related) Organ Failure Assessment (mSOFA); Confusion, Urea, Respiratory rate, 
Blood pressure and Age (CURB-65) and Pneumonia Severity Index (PSI) Error bars denote 95% confidence intervals. The x-axis for mSOFA score was winsorized for values 
higher than 7 points for illustration.  
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Figure E3. Scores and in-hospital mortality / 3 days of ICU stay (complete-case analysis) 
Panel A: systemic inflammatory response syndrome (SIRS) criteria; Panel B: quick Sequential (Sepsis-related); Panel C: Confusion, Respiratory rate and 
Blood pressure (CRB) points; Panel D: modified Sequential (Sepsis-related) Organ Failure Assessment (mSOFA) points; Panel E: Confusion, Urea, 
Respiratory rate, Blood pressure and Age (CURB-65) points and Panel F: Pneumonia Severity Index (PSI) risk class.   
Error bars denote 95% confidence intervals. The x-axis for mSOFA score was winsorized for values higher than 7 points for illustration. 
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Figure E4. Scores and 30-day mortality (complete-case analysis) 
Panel A: systemic inflammatory response syndrome (SIRS) criteria; Panel B: quick Sequential (Sepsis-related); Panels C: Confusion, Respiratory rate and Blood pressure (CRB) 
points, Panel D: modified Sequential (Sepsis-related) Organ Failure Assessment (mSOFA) points; Panel E: Confusion, Urea, Respiratory rate, Blood pressure and Age (CURB-
65) points and Panel F: Pneumonia Severity Index (PSI). Error bars denote 95% confidence intervals. The x-axis for mSOFA score was winsorized for values higher than 7 
points for illustration.  
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Figure E5. Discrimination and Calibration of SIRS, qSOFA, CRB, mSOFA, CURB-65 and PSI scores and their additional contribution to a 
baseline risk model for in-hospital mortality 
 
 
 
Panel A shows the scores discrimination evaluated through the area under the receiver operating characteristic curve (AUROC) for in-hospital mortality in 6,024 patients with community-acquired 
pneumonia. Panel B shows the scores calibration for in-hospital mortality in 6,024 patients with community-acquired pneumonia. Calibration curves assessed by nonparametric smoothed methods.  
CRB - Confusion, Respiratory rate and Blood pressure; CURB-65 - Confusion, Urea, Respiratory rate, Blood pressure and Age; mSOFA - Sequential (Sepsis-related) Organ Failure Assessment; PSI – 
Pneumonia Severity Index; qSOFA – quick Sequential (Sepsis-related) Organ Failure Assessment; ROC - receiver operating characteristic curve; SIRS – systemic inflammatory response syndrome. 
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Table E4. Subgroups analysis regarding discrimination for in-hospital mortality 
 Age Chronic comorbidity 
 Age <65 Age ≥65 Without chronic  comorbidities 
At least 1 chronic c 
comorbidity 
 AUROC 
(95% CI) 
AUROC 
(95% CI) 
AUROC 
(95% CI) 
AUROC 
(95% CI) 
SIRS 0.591 (0.524-0.656) 0.573 (0.543-0.603) 0.594 (0.517-0.668) 0.578 (0.547-0.608) 
qSOFA 0.733 (0.674-0.791) 0.669 (0.640-0.696) 0.708 (0.642-0.772) 0.676 (0.647-0.706) 
CRB 0.767 (0.709-0.821) 0.685 (0.655-0.713) 0.731 (0.662-0.793) 0.699 (0.669-0.729) 
mSOFA 0.874 (0.829-0.913) 0.687 (0.653-0.720) 0.786 (0.723-0.843) 0.733 (0.701-0.763) 
CURB-65 0.772 (0.714-0.826) 0.687 (0.658-0.717) 0.782 (0.727-0.835) 0.713 (0.683-0.741) 
PSI 0.848 (0.801-0.894) 0.715 (0.690-0.740) 0.839 (0.784-0.886) 0.730 (0.704-0.754) 
ROC curve 
 comparisons: 
SIRS vs. qSOFA (p<0.001), 
SIRS vs. CRB (p<0.001), 
SIRS vs. mSOFA (p<0.001), 
SIRS vs. CURB-65 (p<0.001), 
SIRS vs. PSI (p<0.001), 
qSOFA vs. CRB (p=0.108), 
qSOFA vs. mSOFA (p<0.001), 
qSOFA vs. CURB-65 (p=0.057), 
qSOFA vs. PSI (p<0.001), 
CRB vs. mSOFA (p=0.001), 
CRB vs. CURB-65 (p=0.545), 
CRB vs. PSI (p=0.005), 
mSOFA vs. CURB-65 (p=0.001), 
mSOFA vs. PSI (p=0.323), 
CURB-65 vs. PSI (p=0.007) 
SIRS vs. qSOFA (p<0.001), 
SIRS vs. CRB (p<0.001), 
SIRS vs. mSOFA (p<0.001), 
SIRS vs. CURB-65 (p<0.001), 
SIRS vs. PSI (p<0.001), 
qSOFA vs. CRB (p=0.169), 
qSOFA vs. mSOFA (p=0.320), 
qSOFA vs. CURB-65 (p=0.142), 
qSOFA vs. PSI (p=0.003), 
CRB vs. mSOFA (p=0.916) 
CRB vs. CURB-65 (p=0.659), 
CRB vs. PSI (p=0.039), 
mSOFA vs. CURB-65 (p=0.967) 
mSOFA vs. PSI (p=0.116) 
CURB-65 vs. PSI (p=0.053) 
SIRS vs. qSOFA (p=0.003), 
SIRS vs. CRB (p=0.002), 
SIRS vs. mSOFA (p<0.001), 
SIRS vs. CURB-65 (p<0.001), 
SIRS vs. PSI (p<0.001), 
qSOFA vs. CRB (p=0.436), 
qSOFA vs. mSOFA (p=0.035), 
qSOFA vs. CURB-65 (p=0.010), 
qSOFA vs. PSI (p<0.001), 
CRB vs. mSOFA (p=0.180) 
CRB vs. CURB-65 (p=0.019), 
CRB vs. PSI (p=0.004), 
mSOFA vs. CURB-65 (p=0.923) 
mSOFA vs. PSI (p=0.195) 
CURB-65 vs. PSI (p=0.037) 
SIRS vs. qSOFA (p<0.001), 
SIRS vs. CRB (p<0.001), 
SIRS vs. mSOFA (p<0.001), 
SIRS vs. CURB-65 (p<0.001), 
SIRS vs. PSI (p<0.001), 
qSOFA vs. CRB (p=0.032), 
qSOFA vs. mSOFA (p=0.001), 
qSOFA vs. CURB-65 (p=0.005), 
qSOFA vs. PSI (p=0.001), 
CRB vs. mSOFA (p=0.062) 
CRB vs. CURB-65 (p=0.145), 
CRB vs. PSI (p=0.043), 
mSOFA vs. CURB-65 (p=0.280) 
mSOFA vs. PSI (p=0.911) 
CURB-65 vs. PSI (p=0.183) 
 
 
AUROC: area under the receiver operating characteristic curve; CI: confidence interval; CRB: Confusion, Respiratory rate and 
Blood pressure; CURB-65 - Confusion, Urea, Respiratory rate, Blood pressure and Age; mSOFA: modified Sequential (Sepsis-
related) Organ Failure Assessment; PSI – Pneumonia Severity Index; qSOFA: quick Sequential (Sepsis-related) Organ Failure 
Assessment; SIRS: systemic inflammatory response syndrome.!  
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Table E5. Scores performance and clinical utility for in-hospital mortality by each cohort. 
  Discrimination Calibration Overall performance  Clinical utility 
 
Score AUROC (95% CI) 
Hosmer- 
Lemeshow 
test 
Global 
calibration 
test* 
Scaled 
Brier 
score 
Nagelkerke 
R-square Score category 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Barcelona 
SIRS 0.575 (0.547-0.602) 0.778 0.028 0.1% 1.2% SIRS≥2 89 (86-92) 20 (19-21) 7 (7-8) 96 (95-98) 1.12 (1.08-1.17) 0.52 (0.39-0.71) 
qSOFA 0.691 (0.665-0.718) 0.302 0.054 3.1% 8.5% qSOFA≥2 52 (47-57) 80 (79-81) 15 (13-17) 96 (95-97) 2.59 (2.31-2.91) 0.60 (0.54-0.67) 
CRB 0.712 (0.686-0.738) 0.996 0.312 4.8% 10.5% CRB≥2 40 (35-46) 86 (85-87) 17 (14-20) 95 (95-96) 2.91 (2.52-3.36) 0.69 (0.64-0.75) 
mSOFA 0.746 (0.718-0.773) 0.990 0.512 8.1% 17.8% mSOFA≥2 88 (84-91) 37 (36-38) 9 (8-10) 98 (97-98) 1.39 (1.34-1.46) 0.33 (0.25-0.43) 
CURB-65 0.741 (0.717-0.764) 0.883 0.010 6.3% 12.5% CURB-65≥2 78 (73-82) 59 (58-61) 12 (10-13) 97 (97-98) 1.91 (1.79-2.03) 0.37 (0.31-0.46) 
PSI 0.777 (0.757-0.796) 0.999 0.562 6.5% 17.3% PSI ≥4 93 (90-96) 46 (44-47) 11 (10-12) 99 (98-99) 1.71 (1.65-1.78) 0.15 (0.10-0.22) 
AUROC 
curve 
comparisons: 
SIRS vs: qSOFA (p<0.001), CRB (p<0.001), mSOFA (p<0.001), CURB-65 (p<0.001), PSI (p<0.001) 
qSOFA vs: CRB (p=0.049), mSOFA (p<0.001), CURB-65 (p<0.001), PSI (p<0.001) 
CRB vs: mSOFA (p=0.032), CURB-65 (p<0.001), PSI (p<0.001) 
mSOFA vs: CURB-65 (p= 0.799), PSI (p=0.047) 
CURB-65 vs: PSI (p=0.001) 
       
Valencia 
SIRS 0.547 (0.413-0.675) 0.999 0.361 1.1% 0.1% SIRS≥2 79 (54-94) 33 (29-37) 4 (2-7) 98 (94-99) 1.18 (0.93-1.50) 0.64 (0.27-1.54) 
qSOFA 0.702 (0.587-0.807) 0.999 0.393 1.9% 7.7% qSOFA≥2 21 (6-46) 95 (92-96) 12 (4-29) 97 (95-98) 3.95 (1.54-10.15) 0.83 (0.66-1.05) 
CRB 0.705 (0.585-0.819) 0.998 0.545 1.9% 9.5% CRB≥2 26 (9-51) 95 (93-97) 17 (6-36) 97 (95-99) 5.77 (2.47-13.47) 0.77 (0.59-1.01) 
mSOFA 0.791 (0.694-0.877) 0.994 0.037 2.0% 12.7% mSOFA≥2 95 (74-100) 40 (35-44) 5 (3-8) 100 (97-100) 1.57 (1.38-1.78) 0.13 (0.02-0.90) 
CURB-65 0.792 (0.665-0.897) 0.999 0.668 7.9% 16.9% CURB-65≥2 84 (60-97) 70 (66-74) 9 (5-14) 99 (98-100) 2.79 (2.20-3.52) 0.23 (0.08-0.64) 
PSI 0.773 (0.653-0.877) 0.774 0.022 7.9% 14.6% PSI ≥4 74 (49-91) 61 (57-66) 6 (4-11) 98 (96-100) 1.91 (1.43-2.55) 0.43 (0.20-0.91) 
AUROC curve 
comparisons: 
SIRS vs: qSOFA (p=0.023), CRB (p=0.037), mSOFA (p=0.004), CURB-65 (p=0.001), PSI (p=0.001) 
qSOFA vs: CRB (p=0.950), mSOFA (p=0.141),  CURB-65 (p=0.029), PSI (p=0.250) 
CRB vs: mSOFA (p=0.168), CURB-65 (p=0.065), PSI (p=0.315) 
mSOFA vs: CURB-65 (p= 0.980), PSI (p=0.547) 
CURB-65 vs: PSI (p=0.684) 
AUROC: area under the receiver operating characteristic curve; CI: confidence interval; CRB: Confusion, Respiratory rate and Blood pressure; CURB-65 - Confusion, Urea, Respiratory rate, Blood 
pressure and Age; LR+: positive likelihood ratio; LR-: negative likelihood ratio; mSOFA: modified Sequential (Sepsis-related) Organ Failure Assessment; NPV: negative predictive value; PPV: positive 
predictive value; PSI – Pneumonia Severity Index; qSOFA: quick Sequential (Sepsis-related) Organ Failure Assessment; SIRS: systemic inflammatory response syndrome.. * le Cessie-van Houwelingen-
Copas-Hosmer test.!  
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Table E6. Scores performance and clinical utility for in-hospital mortality in 6,874 patients with community-acquired pneumonia 
(imputed analysis) 
 Discrimination Calibration Overall performance  Clinical utility 
Score AUROC (95% CI) 
Hosmer- 
Lemeshow 
test 
Global 
calibration 
test* 
Scaled 
Brier 
score 
Nagelkerke 
R-square Score category 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
SIRS 0.575 (0.550-0.601) 0.880 0.317 0.3% 1.1% SIRS≥2 87 (84-90) 22 (21-23) 7 (6-8) 96 (95-97) 1.12 (1.08-1.16) 0.58 (0.45-0.74) 
qSOFA 0.684 (0.660-0.708) 0.366 0.091 3.2% 7.9% qSOFA≥2 48 (44-53) 82 (81-83) 15 (14-17) 96 (95-96) 2.65 (2.37-2.95) 0.63 (0.58-0.69) 
CRB 0.708 (0.684-0.731) 0.707 0.109 4.8% 10.2% CRB≥2 38 (34-43) 87 (86-88) 17 (15-19) 95 (95-96) 2.97 (2.59-3.39) 0.71 (0.66-0.76) 
mSOFA 0.787 (0.765-0.809) 0.162 <0.001 8.2% 17.8% mSOFA≥2 96 (94-98) 24 (23-25) 8 (7-9) 99 (98-99) 1.26 (1.23-1.29) 0.16 (0.10-0.26) 
CURB-65 0.736 (0.714-0.758) 0.860 0.040 6.9% 11.9% CURB-65≥2 86 (82-89) 46 (45-47) 10 (9-11) 98 (97-98) 1.59 (1.52-1.66) 0.31 (0.25-0.39) 
PSI 0.781 (0.763-0.799) 0.999 0.301 7.0% 17.7% PSI≥4 93 (90-95) 47 (46-49) 11 (10-12) 99 (99-99) 1.76 (1.70-1.83) 0.15 (0.11-0.21) 
AUROC 
curve 
comparisons: 
SIRS vs: qSOFA (p<0.001), CRB (p<0.001), mSOFA (p<0.001), CURB-65 (p<0.001), PSI (p<0.001) 
qSOFA vs: CRB (p=0.014), mSOFA (p<0.001), CURB-65 (p=0.002), PSI (p<0.001) 
CRB vs: mSOFA (p<0.001), CURB-65 (p=0.090), PSI (p<0.001) 
mSOFA vs: CURB-65 (p=0.002), PSI (p=0.684) 
CURB-65 vs: PSI (p<0.001) 
       
 
 
AUROC: area under the receiver operating characteristic curve; CI: confidence interval; CRB: Confusion, Respiratory rate and Blood pressure; CURB-65 - Confusion, Urea, Respiratory rate, 
Blood pressure and Age; LR+: positive likelihood ratio; LR-: negative likelihood ratio; mSOFA: modified Sequential (Sepsis-related) Organ Failure Assessment; NPV: negative predictive 
value; PPV: positive predictive value; PSI – Pneumonia Severity Index; qSOFA: quick Sequential (Sepsis-related) Organ Failure Assessment; SIRS: systemic inflammatory response 
syndrome.. * le Cessie-van Houwelingen-Copas-Hosmer test. 
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 Figure E6. Scores discrimination and calibration for in-hospital mortality in imputed data (n=6,874) 
 
 
 
Panel A shows the scores discrimination evaluated through the area under the receiver operating characteristic curve (AUROC) for in-hospital mortality in 6,874 patients with community-acquired 
pneumonia. Panel B shows the scores calibration for in-hospital mortality in 6,874 patients with community-acquired pneumonia. Calibration curves assessed by nonparametric smoothed methods.  
Calibration curves assessed by nonparametric smoothed methods. 
CRB-Confusion, Respiratory rate and Blood pressure; CURB-65-Confusion, Urea, Respiratory rate, Blood pressure and Age; mSOFA–modified Sequential (Sepsis-related) Organ Failure Assessment; 
PSI–Pneumonia Severity Index; qSOFA – quick Sequential (Sepsis-related) Organ Failure Assessment; ROC - receiver operating characteristic curve; SIRS – systemic inflammatory response syndrome. 
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Table E7. Scores performance and clinical utility for in-hospital mortality / 3 ICU/HDU days in 6,024 patients with community-
acquired pneumonia (complete-case analysis) 
 Discrimination Calibration Overall performance  Clinical utility 
Score AUROC (95% CI) 
Hosmer- 
Lemeshow 
test 
Global 
calibration 
test* 
Scaled 
Brier 
score 
Nagelkerke 
R-square Score category 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
SIRS 0.602 (0.581-0.623) 0.120 0.007 1.1% 2.6% SIRS≥2 90 (88-93) 22 (21-23) 12 (11-13) 95 (94-96) 1.16 (1.13-1.20) 0.43 (0.34-0.55) 
qSOFA 0.692 (0.672-0.711) 0.579 0.020 5.4% 10.2% qSOFA≥2 47 (43-51) 82 (81-83) 24 (21-26) 93 (92-94) 2.67 (2.41-2.96) 0.64 (0.60-0.69) 
CRB 0.712 (0.691-0.731) 0.997 0.070 7.5% 12.4% CRB≥2 38 (34-42) 88 (87-89) 27 (24-30) 92 (92-93) 3.17 (2.80-3.59) 0.71 (0.66-0.75) 
mSOFA 0.752 (0.731-0.773) 0.972 0.323 11.8% 17.7% mSOFA≥2 89 (86-91) 38 (37-40) 14 (13-15) 97 (96-97) 1.44 (1.40-1.50) 0.29 (0.23-0.36) 
CURB-65 0.708 (0.686-0.728) 0.883 0.081 6.4% 11.0% CURB-65≥2 72 (68-76) 61 (60-63) 18 (16-19) 95 (94-96) 1.86 (1.75-1.97) 0.46 (0.40-0.52) 
PSI 0.729 (0.710-0.749) 0.115 0.001 6.6% 13.0% PSI≥4 85 (82-88) 48 (47-49) 16 (15-17) 97 (96-97) 1.64 (1.57-1.71) 0.31 (0.26-0.38) 
AUROC curve 
comparisons: 
SIRS vs: qSOFA (p<0.001), CRB (p<0.001), mSOFA (p<0.001), CURB-65 (p<0.001), PSI (p<0.001) 
qSOFA vs: CRB (p=0.015), mSOFA (p<0.001), CURB-65 (p=0.106), PSI (p=0.001) 
CRB vs: mSOFA (p=0.001), CURB-65 (p=0.421), PSI (p=0.093) 
mSOFA vs.: CURB-65 (p<0.001), PSI (p=0.062) 
CURB-65 vs.: PSI (p=0.009) 
 
       
 
AUROC: area under the receiver operating characteristic curve; CI: confidence interval; CRB: Confusion, Respiratory rate and Blood pressure; CURB-65 - Confusion, Urea, Respiratory rate, 
Blood pressure and Age; LR+: positive likelihood ratio; LR-: negative likelihood ratio; mSOFA: modified Sequential (Sepsis-related) Organ Failure Assessment; NPV: negative predictive 
value; PPV: positive predictive value; PSI – Pneumonia Severity Index; qSOFA: quick Sequential (Sepsis-related) Organ Failure Assessment; SIRS: systemic inflammatory response 
syndrome.. * le Cessie-van Houwelingen-Copas-Hosmer test.   
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 Figure E7. Scores discrimination and calibration for in-hospital mortality / 3 days of ICU stay in complete-case analysis (n=6,024) 
 
 
Panel A shows the scores discrimination evaluated through the area under the receiver operating characteristic curve (AUROC) for in-hospital mortality / 3 days of ICU stay in 6,024 patients with 
community-acquired pneumonia. Panel B shows the scores calibration for in-hospital mortality / 3 days of ICU stay in 6,024 patients with community-acquired pneumonia. Calibration curves assessed 
by nonparametric smoothed methods. 
 
CRB - Confusion, Respiratory rate and Blood pressure; CURB-65 - Confusion, Urea, Respiratory rate, Blood pressure and Age; mSOFA-modified Sequential (Sepsis-related) Organ Failure Assessment; 
PSI–Pneumonia Severity Index; qSOFA – quick Sequential (Sepsis-related) Organ Failure Assessment; ROC - receiver operating characteristic curve; SIRS – systemic inflammatory response syndrome.  
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Table E8. Scores performance and clinical utility for 30-day mortality in 6,024 patients with community-acquired pneumonia 
(complete case analysis) 
 Discrimination Calibration Overall performance  Clinical utility 
Score AUROC (95% CI) 
Hosmer- 
Lemeshow 
test 
Global 
calibration 
test* 
Scaled 
Brier 
score 
Nagelkerke 
R-square Score category 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
SIRS 0.572 (0.546-0.598) 0.578 0.028 1.0% 1.1% SIRS≥2 89 (85-92) 22 (20-23) 8 (7-9) 96 (95-97) 1.13 (1.09-1.17) 0.53 (0.40-0.70) 
qSOFA 0.690 (0.665-0.715) 0.473 0.086 4.1% 8.7% qSOFA≥2 49 (44-54) 82 (81-83) 17 (15-19) 95 (95-96) 2.69 (2.40-3.01) 0.62 (0.56-0.68) 
CRB 0.705 (0.680-0.730) 0.995 0.492 5.6% 10.4% CRB≥2 39 (34-44) 87 (86-88) 18 (16-21) 95 (94-96) 2.95 (2.56-3.40) 0.71 (0.65-0.76) 
mSOFA 0.739 (0.712-0.764) 0.975 0.036 7.1% 13.5% mSOFA≥2 88 (84-91) 37 (36-38) 10 (9-11) 98 (97-98) 1.40 (1.34-1.46) 0.33 (0.25-0.43 ) 
CURB-65 0.743 (0.720-0.766) 0.877 0.006 5.5% 13.1% CURB-65≥2 77 (73-81) 60 (59-61) 13 (12-14) 97 (97-98) 1.94 (1.82-2.06) 0.38 (0.32-0.45) 
PSI 0.786 (0.767-0.804) 0.999 0.304 8.7% 19.0% PSI≥4 92 (89-95) 48 (47-50) 12 (11-13) 99 (98-99) 1.78 (1.72-1.85) 0.16 (0.11-0.22) 
AUROC curve 
comparisons: 
SIRS vs: qSOFA (p<0.001), CRB (p<0.001), mSOFA (p<0.001), CURB-65 (p<0.001), PSI (p<0.001) 
qSOFA vs: CRB (p=0.127), mSOFA (p=0.001), CURB-65 (p<0.001), PSI (p<0.001) 
CRB vs: mSOFA (p=0.027), CURB-65 (p<0.001), PSI (p<0.001) 
mSOFA vs.: CURB-65 (p=0.746), PSI (p=0.001) 
CURB-65 vs.: PSI (p<0.001) 
 
       
 
AUROC: area under the receiver operating characteristic curve; CI: confidence interval; CRB: Confusion, Respiratory rate and Blood pressure; CURB-65 - Confusion, Urea, 
Respiratory rate, Blood pressure and Age; LR+: positive likelihood ratio; LR-: negative likelihood ratio; mSOFA: modified Sequential (Sepsis-related) Organ Failure Assessment; 
NPV: negative predictive value; PPV: positive predictive value; PSI – Pneumonia Severity Index; qSOFA: quick Sequential (Sepsis-related) Organ Failure Assessment; SIRS: 
systemic inflammatory response syndrome.. * le Cessie-van Houwelingen-Copas-Hosmer test. 
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Figure E8. Scores discrimination and calibration for 30-day mortality in complete-case analysis (n=6,024) 
 
 
Panel A shows the scores discrimination evaluated through the area under the receiver operating characteristic curve (AUROC) for 30-day mortality in 6,024 patients with community-acquired 
pneumonia. Panel B shows the scores calibration for 30-day mortality in 6,024 patients with community-acquired pneumonia. Calibration curves assessed by nonparametric smoothed methods. 
 
CRB - Confusion, Respiratory rate and Blood pressure; CURB-65 - Confusion, Urea, Respiratory rate, Blood pressure and Age; mSOFA - modified Sequential (Sepsis-related) Organ Failure 
Assessment; PSI – Pneumonia Severity Index; qSOFA – quick Sequential (Sepsis-related) Organ Failure Assessment; ROC - receiver operating characteristic curve; SIRS – systemic 
inflammatory response syndrome. 
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Table E9. qSOFA, CRB, qSOFA-65, CRB-65 performance and clinical utility for in-hospital mortality in 6,024 patients with community-acquired pneumonia  
 Discrimination Calibration Overall performance  Clinical utility 
Score AUROC (95% CI) 
Hosmer- 
Lemeshow 
test 
Global 
calibration 
test* 
Scaled 
Brier 
score 
Nagelkerke 
R-square Score category 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
qSOFA 0.697 (0.671-0.722) 0.494 0.036 4.3% 8.8% qSOFA≥2 50 (45-55) 81 (80-82) 15 (13-17) 96 (96-97) 2.70 (2.41-3.03) 0.61 (0.55-0.68) 
CRB 0.716 (0.690-0.741) 0.997 0.224 4.3% 10.7% CRB≥2 40 (35-45) 87 (86-88) 17 (14-20) 96 (95-96) 3.05 (2.65-3.51) 0.69 (0.64-0.75) 
qSOFA-65 0.726 (0.702-0.750) 0.198 0.009 4.2% 10.9% qSOFA-65≥2 85 (81-89) 48 (46-49) 10 (9-11) 98 (97-98) 1.63 (1.55-1.71) 0.31 (0.25-0.40) 
CRB-65 0.743 (0.720-0.766) 0.592 0.015 5.9% 12.7% CRB-65≥2 75 (71-79) 64 (63-66) 12 (11-14) 98 (97-98) 2.11 (1.97-2.26) 0.39 (0.32-0.46) 
AUROC curve 
comparisons: 
qSOFA vs: CRB (p=0.055), qSOFA-65 (p<0.001), CRB-65 (p<0.001) 
CRB vs: qSOFA-65 (p=0.378), CRB-65 (p<0.001) 
qSOFA-65 vs: CRB-65 (p=0.037) 
       
Figure E9. qSOFA, CRB, qSOFA-65, CRB-65 discrimination and calibration for in-hospital mortality in 6,024 patients with community-acquired pneumonia. 
AUROC: area under the receiver operating characteristic curve; CI: confidence interval; CRB: Confusion, Respiratory rate and Blood pressure; CRB-65 - Confusion, Respiratory rate, Blood pressure and Age; LR+: 
positive likelihood ratio; LR-: negative likelihood ratio; NPV: negative predictive value; PPV: positive predictive value; qSOFA: quick Sequential (Sepsis-related) Organ Failure Assessment; qSOFA-65: quick 
Sequential (Sepsis-related) Organ Failure Assessment plus Age . * le Cessie-van Houwelingen-Copas-Hosmer test.  
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Table E10. Additional predictive performance contribution of scores to a baseline risk model with demographic and chronic comorbidities 
 
 Discrimination Discrimination improvement Calibration Overall performance 
 AUROC (95% CI) 
IDI 
Baseline + Score  
vs. Baseline 
(95% CI) 
Hosmer 
Lemeshow 
test 
Global 
calibration 
Test* 
Scaled Brier 
score 
 
Nagelkerke 
R square 
Baseline model 0.745 (0.723-0.766) - 0.031 <0.001 4.8% 11.8% 
Baseline + SIRS 0.752 (0.731-0.774) 0.007 (0.004-0.010) 0.077 0.022 4.8% 13.0% 
Baseline + qSOFA 0.780 (0.760-0.800) 0.022 (0.016-0.028) 0.004 <0.001 6.5% 15.7% 
Baseline + CRB 0.794 (0.775-0.813) 0.033 (0.025-0.040) 0.010 <0.001 6.5% 17.4% 
Baseline + mSOFA 0.836 (0.818-0.854) 0.095 (0.081-0.110) 0.768 0.035 13.2% 25.4% 
 
AUROC comparisons:  
Baseline vs. +SIRS (p=0.065),  
Baseline vs. +qSOFA (p<0.001),  
Baseline vs. +CRB (p<0.001),  
Baseline vs. +mSOFA (<0.001), 
Baseline + SIRS vs. +qSOFA (p<0.001),  
Baseline + SIRS vs. +CRB (p<0.001),  
Baseline + SIRS vs. +mSOFA (p<0.001),
Baseline + qSOFA. vs. +CRB (0.007),  
Baseline + qSOFA. vs. +mSOFA (p<0.001), 
Baseline + CRB vs. +mSOFA (p<0.001). 
IDI comparison among models 
+ SIRS vs. +qSOFA: 0.015 (0.008-0.021), 
+ SIRS vs. +CRB: 0.025 (0.017-0.034), 
+ SIRS vs. +mSOFA: 0.088 (0.073-0.103),
+ qSOFA vs. +CRB: 0.011 (0.005-0.016), 
+qSOFA vs. +mSOFA: 0.073 (0.060-0.086), 
+ CRB vs. +mSOFA: 0.063 (0.050-0.076). 
AUROC: area under the receiver operating characteristic curve; CI: confidence interval; CRB: Confusion, Respiratory rate and Blood 
pressure; IDI: Integrated Discrimination Index; mSOFA: modified Sequential (Sepsis-related) Organ Failure Assessment; qSOFA: quick 
Sequential (Sepsis-related) Organ Failure Assessment; SIRS: systemic inflammatory response syndrome. * le Cessie-van Houwelingen-
Copas-Hosmer test.  
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Figure E10. Discrimination and Calibration of SIRS, qSOFA, CRB and mSOFA scores and their additional contribution to a baseline risk 
model for in-hospital mortality 
 
Panel A shows the discrimination of baseline risk model and additional models with each score, estimated through a logistic regression model, for in-hospital mortality in the multiple imputed data 
(n=6,874 patients). Panel B  shows the calibration of the baseline risk model and additional models with each score for in-hospital mortality in the multiple imputed data (n=6,874 patients). Calibration 
curves assessed by nonparametric smoothed methods.  The baseline risk model included demographic (age, gender) and, comorbidity variables (chronic respiratory disease, chronic neurologic disease, 
liver disease, heart failure, diabetes mellitus, neoplasia, chronic renal disease, and etiologic diagnosis). 
 
CRB - Confusion, Respiratory rate and Blood pressure; mSOFA - modified Sequential (Sepsis-related) Organ Failure Assessment; qSOFA – quick Sequential (Sepsis-related) Organ Failure Assessment; 
ROC - receiver operating characteristic curve; SIRS – systemic inflammatory response syndrome.  
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Table E11. Clinical utility of SIRS, qSOFA, CRB, mSOFA, CURB-65 and PSI among 
subgroups for in-hospital mortality (complete-case analysis, n=6,024)* 
 <65 years 
 Sensitivity Specificity PPV NPV LR+ LR- 
SIRS≥2 86 (75-93) 24 (22-25) 3 (3-4) 98 (97-99) 1.12 (1.01-1.24) 0.62 (0.35-1.10) 
qSOFA≥2 51 (38-63) 86 (85-88) 10 (7-14) 98 (98-99) 3.71 (2.88-4.79) 0.57 (0.45-0.73) 
CRB≥2 42 (30-55) 92 (91-93) 14 (9-19) 98 (97-99) 5.26 (3.86-7.17) 0.63 (0.52-0.77) 
mSOFA≥2 94 (86-98) 51 (49-53) 6 (4-7) 100 (99-100) 1.94 (1.80-2.08) 0.11 (0.04-0.29) 
CURB-65≥2 46 (34-59) 90 (88-91) 12 (8-17) 98 (98-99) 4.51 (3.41-5.98) 0.60 (0.48-0.74) 
PSI≥4 81 (70-90) 79 (77-81) 11 (8-14) 99 (99-100) 3.89 (3.38-4.47) 0.24 (0.15-0.39) 
 >=65 years 
 Sensitivity Specificity PPV NPV LR+ LR- 
SIRS≥2 90 (86-93) 20 (19-22) 9 (8-10) 95 (94-97) 1.12 (1.08-1.17) 0.52 (0.37-0.72) 
qSOFA≥2 50 (45-56) 78 (77-79) 17 (15-20) 95 (94-95) 2.29 (2.01-2.60) 0.64 (0.57-0.71) 
CRB≥2 39 (34-45) 84 (82-85) 18 (15-21) 94 (93-95) 2.39 (2.04-2.80) 0.73 (0.66-0.80) 
mSOFA≥2 87 (83-90) 28 (26-29) 10 (9-11) 96 (94-97) 1.20 (1.14-1.26) 0.48 (0.35-0.64) 
CURB-65≥2 85 (81-89) 40 (39-42) 11 (10-13) 97 (96-98) 1.43 (1.35-1.50) 0.37 (0.28-0.48) 
PSI≥4 95 (92-97) 25 (24-27) 10 (9-12) 98 (97-99) 1.27 (1.23-1.31) 0.21 (0.13-0.34) 
 Without chronic comorbidities 
 Sensitivity Specificity PPV NPV LR+ LR- 
SIRS≥2 84 (71-93) 25 (23-27) 3 (2-4) 98 (97-99) 1.11 (0.98-1.26) 0.65 (0.34-1.24) 
qSOFA≥2 42 (28-57) 87 (85-89) 8 (5-12) 98 (98-99) 3.24 (2.30-4.58) 0.67 (0.53-0.84) 
CRB≥2 32 (20-47) 91 (90-92) 9 (5-14) 98 (97-99) 3.58 (2.33-5.50) 0.75 (0.62-0.90) 
mSOFA≥2 88 (76-95) 51 (48-53) 4 (3-6) 99 (99-100) 1.79 (1.60-2.00) 0.24 (0.11-0.50) 
CURB-65≥2 68 (53-80) 76 (74-78) 7 (5-10) 99 (98-99) 2.85 (2.32-3.51) 0.42 (0.28-0.63) 
PSI≥4 84 (71-93) 74 (71-76) 8 (6-10) 99 (99-100) 3.17 (2.75-3.66) 0.22 (0.12-0.41) 
 At least 1 chronic comorbidity 
 Sensitivity Specificity PPV NPV LR+ LR- 
SIRS≥2 90 (86-93) 20 (19-22) 9 (8-10) 96 (94-97) 1.13 (1.08-1.17) 0.50 (0.35-0.70) 
qSOFA≥2 51 (46-57) 79 (77-80) 17 (15-20) 95 (94-96) 2.39 (2.10-2.71) 0.62 (0.55-0.70) 
CRB≥2 41 (36-47) 85 (84-86) 19 (16-23) 94 (93-95) 2.75 (2.35-3.22) 0.69 (0.63-0.76) 
mSOFA≥2 90 (86-93) 29 (28-31) 10 (9-11) 97 (96-98) 1.27 (1.21-1.32) 0.35 (0.25-0.50) 
CURB-65≥2 80 (75-85) 51 (49-53) 13 (11-14) 97 (96-98) 1.64 (1.53-1.75) 0.39 (0.31-0.49) 
PSI≥4 93 (89-96) 34 (32-35) 11 (10-12) 98 (97-99) 1.40 (1.35-1.46) 0.21 (0.14-0.32) 
*95% confidence interval between brackets  
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Figure E11. Decision-curve analysis for in-hospital mortality using Baseline Risk Models Scores in imputed data 
 
Panel A shows the net benefit (NB = benefit x true-positive classifications minus harm/cost x false-positive classifications) of each model and the strategy to treat-none and treat-all patients over the 
plausible range of number willing to treat (NWT) (i.e., threshold probabilities). Panel B shows the net reduction in interventions in a theoretical population of 100 patients by using the models to make 
clinical decisions.  
 
CRB - Confusion, Respiratory rate and Blood pressure; mSOFA - modified Sequential (Sepsis-related) Organ Failure Assessment; qSOFA – quick Sequential (Sepsis-related) Organ Failure Assessment; ROC - receiver operating 
characteristic curve; SIRS – systemic inflammatory response syndrome. 
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Figure E12. In-hospital mortality stratified by SIRS, qSOFA CRB and mSOFA categories in the imputed data 
 
 
Figure E13. In-hospital mortality stratified by SIRS, qSOFA, CRB and mSOFA categories in patients without 
and with chronic comorbidities (complete-case analysis) 
 
 
 
CRB - Confusion, Respiratory rate and Blood pressure; qSOFA – quick Sequential (Sepsis-related) Organ Failure Assessment; SIRS 
– systemic inflammatory response syndrome; mSOFA – modified Sequential (Sepsis-related) Organ Failure Assessment.  
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